市場調査レポート

商品コード

1624374

NGSベースRNA-Seqの世界市場規模：製品・サービス別、技術別、用途別、エンドユーザー別、地域別、範囲および予測

Global NGS-based RNA-seq Market Size By Product And Service, By Technology, By Application, By End-User, By Geographic Scope And Forecast

出版日: 2024年08月11日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日

価格

PDF (Single User License)

USD 3,950 577,016円

1名のみが、レポートにアクセスする事ができるライセンスです。レポートPDFのダウンロード、印刷は可能です。

PDF & Excel (5 User License)

USD 4,850 708,488円

5名までが、レポートにアクセスする事ができるライセンスです。レポートPDF・関連するExcelシートのダウンロード、印刷は可能です。

PDF & Excel (Enterprise User License)

USD 7,550 1,102,904円

人数制限なく、レポートにアクセスできるライセンスです。PDF形式のレポートと関連するExcel出力シートの両方をダウンロード、印刷する事が可能です。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=146.08円

全表示
概要
目次

概要

サンプル依頼リストに入れる

NGSベースRNA-Seq市場規模と予測

NGSベースRNA-Seq市場規模は、2023年に31億7,000万米ドルと評価され、2031年には128億1,000万米ドルに達すると予測され、2024年から2031年までのCAGRは19.05%で成長する見込みです。NGSベースRNA-Seq（次世代シーケンサーベースのRNAシーケンシング）は、サンプルの全RNA含有量の徹底的な調査と定量化を可能にする技術です。NGSベースRNA-Seqは、RNAをcDNA断片のライブラリに変換し、それをハイスループットシーケンシング法を用いて読み取ることで、既知および新規の転写産物の発見、遺伝子発現レベルの定量化、代替スプライシングイベントの発見などの知見を得ることができます。NGSベースRNA-Seqは、基礎研究や臨床診断など多くの用途があります。研究においては、様々な状況下での遺伝子発現パターンを調査し、疾患の原因を分子レベルで理解し、将来の治療ターゲットを見つけるために使用されます。

さらに、病原体の検出と特徴付けを可能にすることで感染症の研究にも、作物や家畜の遺伝子改良のための農業にも有用です。

世界のNGSベースRNA-Seq市場力学

NGSベースRNA-Seq市場を形成している主な市場力学

主な市場促進要因

技術の進歩：

次世代シーケンシング（NGS）技術の絶え間ない改良により、RNAシーケンシングの速度と精度が向上する一方でコストが大幅に削減されました。このため、NGSベースRNA-Seqは研究および臨床診断にとってより利用しやすく、望ましいものとなり、市場の成長をもたらしています。

個別化医療に対する需要の増加：

NGSベースRNA-Seqは、個別化治療の開発に必要な疾患の遺伝的基盤の理解に不可欠となっています。個別化治療アプローチが重視されるようになったことで、臨床現場におけるRNA-Seqのニーズが高まっています。

遺伝子調査の増加：

特にがん、神経学、感染症などの遺伝学的研究が増加しています。NGSベースRNA-Seqは、遺伝子発現、制御、スプライシングに関する詳細な洞察を提供するため、これらの研究領域での進歩が可能になり、市場を促進しています。

創薬および開発における応用の拡大：

NGSベースRNA-Seqは、新しい治療標的を見つけ、ゲノムレベルでの薬物反応をよりよく理解するために、医薬品の研究開発でますます活用されるようになっています。このアプリケーションはRNA-Seq市場の主要な促進要因です。

主な課題：

高いデータ管理要件：

NGSベースRNA-Seqでは大量のデータが作成されるため、データの保存、管理、解析に大きなハードルがあります。データを扱い理解するための高度なバイオインフォマティクスツールや知識の必要性は、小規模な研究所や研究機関にとって大きなハードルとなり、市場の成長を制限します。

サンプル調製の複雑さ：

NGSベースRNA-Seqのサンプル調製は複雑でエラーが起こりやすく、結果の精度に影響します。この複雑さにより、訓練を受けたスタッフが必要となり、RNAシーケンシングの取り組みにかかる時間と費用が増大するため、市場の需要が減少します。

コストの制約：

NGS装置の初期費用と、試薬、メンテナンス、データ処理にかかる継続的な費用は、NGS技術のコストが低下しているとはいえ、特定の組織にとっては依然として手の届かないものです。このことが、リソースに制約のある環境におけるRNA-Seqの普及を妨げています。

主要動向：

人工知能と機械学習の統合：

NGSベースRNA-SeqにおけるAIとML技術の利用は、大量のデータを効率的に管理・分析するためにますます普及しています。これらのツールは、研究成果や診断精度を向上させるために、遺伝子発現データの複雑なパターンを特定するのに役立ちます。

シングルセルRNAシーケンシング（scRNA-Seq）の成長：

サンプル内の細胞の変異や機能をより正確に調べることができるため、シングルセルRNAシーケンシングの需要が急速に高まっています。この動向は、シングルセルレベルでの生物学および疾患の理解を根本的に変えつつあります。

マルチプレキシングとハイスループット技術：

マルチプレキシングとハイスループットシーケンシング技術により、多くのサンプルや遺伝子を同時に解析することが可能になった。これにより効率が向上し、サンプルあたりのコストが低下するため、RNA-Seqがより身近になり、研究や臨床診断に広く使用されるようになり、市場の拡大が促進されます。

臨床診断への拡大：

ゲノムレベルでの疾患の発見と理解のために、臨床診断においてNGSベースRNA-Seqを使用する傾向が高まっています。これには、がん診断、感染症、遺伝子異常への応用が含まれ、より個別化された効果的な治療への道が開かれます。

NGS-based RNA-seq Market size was valued at USD 3.17 Billion in 2023 and is projected to reach USD 12.81 Billion by 2031 , growing at a CAGR of 19.05% from 2024 to 2031. NGS-based RNA-seq (Next-Generation Sequencing-based RNA sequencing) is a technology that enables a thorough investigation and quantification of a sample's total RNA content. NGS-based RNA-seq converts RNA into a library of cDNA fragments that are then read using high-throughput sequencing methods, which can discover known and novel transcripts, quantify gene expression levels, and uncover alternative splicing events, among other findings. NGS-based RNA-seq has many applications, including basic research and clinical diagnostics. In research, it is used to investigate gene expression patterns under various situations, gain a molecular understanding of disease causes, and find prospective treatment targets

Furthermore, it is useful in the research of infectious illnesses by allowing for pathogen detection and characterization, as well as in agriculture for crop and livestock genetic improvement.

Global NGS-based RNA-seq Market Dynamics

The key market dynamics that are shaping the NGS-based RNA-seq Market include:

Key Market Drivers

Technological Advancements:

The constant improvement of Next-Generation Sequencing (NGS) technologies has greatly decreased costs while increasing the speed and accuracy of RNA sequencing. This makes NGS-based RNA-seq more accessible and desirable for research and clinical diagnostics, resulting in increased market growth.

Increased Demand for Personalized Medicine:

NGS-based RNA-seq has become crucial for understanding the genetic basis of diseases, which is required for the development of personalized therapy. The rising emphasis on individualized treatment approaches drives up the need for RNA-seq in clinical settings.

Rise in Genetic Research:

There is an increase in genetic research, particularly in cancer, neurology, and infectious disorders. NGS-based RNA-seq gives detailed insights into gene expression, regulation, and splicing, allowing for advances in these study domains and propelling the market.

Expanding Applications in Drug Discovery and Development:

NGS-based RNA-seq is increasingly being utilized in drug research and development to find new therapeutic targets and better understand drug responses at the genomic level. This application is a major driver of the RNA-seq market.

Key Challenges:

High Data Management Requirements:

NGS-based RNA-seq creates massive volumes of data, which presents substantial hurdles in data storage, management, and analysis. This need for sophisticated bioinformatics tools and knowledge to handle and understand data becomes a significant hurdle for smaller laboratories and research institutes, limiting market growth.

Complexity of Sample Preparation:

Sample preparation for NGS-based RNA-seq is complex and error-prone, affecting the accuracy of results. This complexity demands trained staff and increases the time and expense involved with RNA sequencing initiatives, reducing market demand.

Cost Constraints:

The original cost of NGS equipment and continuing expenses for reagents, maintenance, and data processing, even with NGS technology' declining costs, remain unaffordable for certain organizations. This hinders the widespread deployment of RNA-seq in resource-constrained environments.

Key Trends:

Integration of Artificial Intelligence and Machine Learning:

The use of AI and ML technologies in NGS-based RNA-seq is becoming increasingly popular for efficiently managing and analyzing large amounts of data. These tools help to identify complicated patterns in gene expression data for improving research outcomes and diagnosis accuracy.

Single-Cell RNA Sequencing (scRNA-seq) Growth:

Demand for single-cell RNA sequencing is quickly increasing since it allows for a more precise investigation of cellular variations and functions within a sample. This trend is fundamentally changing our understanding of biology and disease at the single-cell level.

Multiplexing and High-Throughput Technologies:

Multiplexing and high-throughput sequencing technologies have made it possible to analyze many samples or genes at the same time. This increases efficiency and lowers the cost per sample, making RNA-seq more accessible and widely used in research and clinical diagnoses, promoting market expansion.

Expansion into Clinical Diagnostics:

There is an increasing trend of using NGS-based RNA-seq in clinical diagnostics to discover and understand disorders at the genomic level. This includes applications in cancer diagnoses, infectious diseases, and genetic abnormalities, paving the path for more personalized and effective therapies.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global NGS-based RNA-seq Market Regional Analysis

Here is a more detailed regional analysis of the NGS-based RNA-seq Market:

North America:

According to Verified Market Research, North America is estimated to dominate in NGS-based RNA-seq Market over the forecast period. North America, particularly the United States, has a strong research infrastructure, including multiple top universities, research organizations, and biotech companies. This climate promotes innovation and rapid adoption of NGS-based RNA-seq technologies, allowing the region to dominate the market

Significant public and private investment in the healthcare and biotechnology industries in North America enables advanced research, development, and application of NGS-based RNA-seq. This financial support speeds up technical breakthroughs and their implementation in healthcare settings.

Personalized medicine is becoming increasingly popular in North America, to tailor medical treatments to individual genetic profiles. NGS-based RNA-seq is critical for understanding genetic variants, thereby, driving its use in both research and clinical diagnostics throughout the region.

Furthermore, the regulatory climate in North America, particularly in the United States, fosters the development and application of NGS-based technologies, thanks to the FDA's proactive approach to genomic and precision medicine. This supporting policy framework shortens the path to market for innovative RNA-seq applications and developments.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR within the NGS-based RNA-seq Market during the forecast period. The region's healthcare sector is expanding rapidly, supported by increased investment and government measures to improve healthcare infrastructure. This expansion encourages the use of modern technologies such as NGS-based RNA-seq in diagnosis and research.

Precision medicine is becoming increasingly important in Asia Pacific countries, to provide patient-specific medicines based on genetic information. As a result of its importance in studying genetic variants, NGS-based RNA-seq is becoming increasingly popular.

The region is experiencing an increase in the prevalence of genetic abnormalities and cancer, necessitating the use of modern diagnostic technologies. NGS-based RNA-seq provides extensive insights into genetic information, allowing for early detection and personalized treatment regimens.

Furthermore, Asia-Pacific is emerging as a hub for biotechnology and pharmaceutical research and development. Governments and commercial organizations are increasing financing for genomics research, accelerating the expansion of NGS-based RNA-seq by providing critical resources for innovation and application in this field.

Europe:

Europe has a rich legacy of international collaborative research, which is encouraged by EU financing programs such as Horizon Europe. These efforts promote the use of NGS-based RNA-seq technologies in a variety of sectors, accelerating growth by pooling resources and expertise.

European countries are investing more in precision medicine, with national and regional initiatives aimed at incorporating genomic data into healthcare. NGS-based RNA-seq is critical for these activities, resulting in increased application in both research and clinical diagnoses.

The most recent genomics technology advancements are being quickly adopted by the European market. This includes NGS-based RNA-seq, which is growing and becoming more accessible across the region because of advances in sequencing efficiency, data processing, and cost reductions, driving market adoption.

Furthermore, the biotech and pharmaceutical industries in Europe are expanding rapidly, with an emphasis on medication discovery and development using genomic data. NGS-based RNA-seq is critical for discovering new therapeutic targets and understanding disease mechanisms, driving its development in these industries.

Global NGS-based RNA-seq Market: Segmentation Analysis

The NGS-based RNA-seq Market is Segmented based on Product & Service, Technology, Application, End-user, And Geography.

NGS-based RNA-seq Market, By Product & Service

Sample Preparation Products
Sequencing Platforms and Consumables
Sequencing Services
Data Analysis, Storage and Management

Based on Product & Service, the market is segmented into Sample Preparation Products, Sequencing Platforms and Consumables, Sequencing Services, and Data Analysis, Storage & Management. The sequencing platforms and consumables segment is estimated to dominate the NGS-based RNA-seq Market due to the critical function these products play throughout the sequencing process. Sequencing platforms and consumables are critical components of RNA sequencing because they have a direct impact on the efficiency, accuracy, and throughput of the sequencing procedures. The high costs of these platforms, along with the continuous requirement for consumables, ensure that this category receives a sizable share of market income.

NGS-based RNA-seq Market, By Technology

Sequencing by Synthesis (SBS)
Ion Semiconductor Sequencing
Single-molecule Real-time Sequencing
Nanopore Sequencing

Based on Technology, the market is segmented into Sequencing by Synthesis (SBS), Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, and Nanopore Sequencing. The sequencing by synthesis (SBS) segment is estimated to grow at the highest CAGR in the NGS-based RNA-seq Market due to its widespread use in academic research and clinical diagnostics due to its high throughput, precision, and cost-effectiveness when compared with other sequencing methods. SBS, as demonstrated by Illumina's sequencing platforms, has established the gold standard in NGS because it delivers a consistent balance of read length and sequencing depth, making it ideal for a wide range of applications, including transcriptome profiling and whole-genome sequencing.

NGS-based RNA-seq Market, By Application

Expression Profiling Analysis
Small RNA Sequencing
De Novo Transcriptome Assembly
Variant Calling and Transcriptome Epigenetics

Based on Application, the market is segmented into Expression Profiling Analysis, Small RNA Sequencing, De Novo Transcriptome Assembly, and Variant Calling & Transcriptome Epigenetics. The expression profiling analysis segment is estimated to exhibit the highest growth within the market over the forecast period due to the crucial role that expression profiling plays in understanding gene function, regulation, and the genetic basis of illness. Expression profiling analysis using NGS-based RNA-seq offers unprecedented depth and breadth in assessing the expression levels of thousands of genes at the same time, providing insights into the molecular signatures of distinct cells and tissues under varied settings.

NGS-based RNA-seq Market, By End-User

Research and Academia
Hospitals and Clinics
Pharmaceutical and Biotechnology Companies
Others

Based on End-User, the market is segmented into Research and Academia, Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, and Others. The research and academia segment is estimated to grow at the highest CAGR in the market over the forecast period owing to the widespread use of NGS-based RNA sequencing in basic and applied research to get an unprecedented understanding of genomic expressions, variants, and functions. Globally, academic and research organizations make significant investments in genomic research, using RNA-seq technology to investigate difficult biological problems, disease processes, and evolutionary studies.

Key Players

The "Global NGS-based RNA-seq Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
Illumina, Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche, QIAGEN, PerkinElmer, Pacific Biosciences of California, Oxford Nanopore Technologies, Novogene Co., BGI, Macrogen, GENEWIZ, Eurofins Genomics, Twist Bioscience Corporation, MGI Tech Co., Paragon Genomics, NanoString Technologies, Lexogen, and Singular Genomics Systems.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

NGS-based RNA-seq Market Recent Developments
In February 2024, Illumina announced its new "NovaSeq X Plus" sequencing equipment, which promises quicker run times and increased throughput for single-cell RNA-seq applications. This technology is intended to be especially useful for researchers investigating intricate biological processes at the cellular level.
In February 2024, BGI and Berry Genomics announced a collaboration to create an AI-powered platform for analyzing RNA-seq data. This platform is intended to increase the accuracy and efficiency of RNA-seq data analysis, resulting in faster and more precise diagnoses and treatment strategies.
In February 2024, NanoString Technologies received FDA approval for its GeoMx NGS Targeted Assay, a next-generation sequencing (NGS) solution for targeted gene expression analysis. This approval opens up new avenues for applying NGS technology in clinical settings.
In February 2024, 10x Genomics and Sema4 announced a collaboration to develop and commercialize spatial transcriptomics technologies. This cooperation seeks to combine 10x Genomics' spatial biology knowledge with Sema4's artificial intelligence and machine learning skills, resulting in advanced solutions for analyzing the spatial distribution of RNA in tissues.

1 INTRODUCTION OF GLOBAL NGS-BASED RNA-SEQ MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL NGS-BASED RNA-SEQ MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
4.5 Regulatory Framework

5 GLOBAL NGS-BASED RNA-SEQ MARKET, BY PRODUCT & SERVICE

5.1 Overview
5.2 Sample Preparation Products
5.3 Sequencing Platforms and Consumables
5.4 Sequencing Services
5.5 Data Analysis, Storage and Management

6 GLOBAL NGS-BASED RNA-SEQ MARKET, BY END-USER

6.1 Overview
6.2 Research and Academia
6.3 Hospitals and Clinics
6.4 Pharmaceutical and Biotechnology Companies
6.5 Others

7 GLOBAL NGS-BASED RNA-SEQ MARKET, BY APPLICATION

7.1 Overview
7.2 Expression Profiling Analysis
7.3 Small RNA Sequencing
7.4 De Novo Transcriptome Assembly
7.5 Variant Calling and Transcriptome Epigenetics

8 GLOBAL NGS-BASED RNA-SEQ MARKET, BY TECHNOLOGY

8.1 Overview
8.2 Sequencing by Synthesis (SBS)
8.3 Ion Semiconductor Sequencing
8.4 Single-molecule Real-time Sequencing
8.5 Nanopore Sequencing

9 GLOBAL NGS-BASED RNA-SEQ MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Argentina
9.6 Rest of the World

10 GLOBAL NGS-BASED RNA-SEQ MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Share
10.3 Vendor Landscape
10.4 Key Development Strategies

11 COMPANY PROFILES

11.1 Illumina
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Thermo Fisher Scientific
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Agilent Technologies
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 F. Hoffmann-La Roche
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 QIAGEN
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 PerkinElmer
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 Pacific Biosciences of California
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Oxford Nanopore Technologies
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Novogene Co.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments
11.10 BGI
- 11.10.1 Overview
- 11.10.2 Financial Performance
- 11.10.3 Product Outlook
- 11.10.4 Key Developments

12 Appendix

12.1 Related Reports

NGSベースRNA-Seqの世界市場規模：製品・サービス別、技術別、用途別、エンドユーザー別、地域別、範囲および予測

Global NGS-based RNA-seq Market Size By Product And Service, By Technology, By Application, By End-User, By Geographic Scope And Forecast

NGSベースRNA-Seq市場規模と予測

世界のNGSベースRNA-Seq市場力学

主な市場促進要因

目次

第1章 世界のNGSベースRNA-Seq市場のイントロダクション

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

第4章 世界のNGSベースRNA-Seq市場の展望

第5章 NGSベースRNA-Seqの世界市場：製品・サービス別

第6章 NGSベースRNA-Seqの世界市場：エンドユーザー別

第7章 NGSベースRNA-Seqの世界市場：用途別

第8章 NGSベースRNA-Seqの世界市場：技術別

第9章 NGSベースRNA-Seqの世界市場：地域別

第10章 世界のNGSベースRNA-Seq市場：競合情勢

第11章 企業プロファイル

第12章 付録

NGS-based RNA-seq Market Size And Forecast